Metabolic Diseases

About 415 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 – 95 percent of all cases. This number is projected to increase to 642 million people by 20401. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, and basal insulin from our alliance partner Eli Lilly and Company, we are also focused on cardiometabolic indications with a high unmet medical need.


Type-2 diabetes mellitus is a chronic progressive disease, which has assumed the status of a global pandemic. At-present, diabetes affects 415 million people globally, and the number is predicted to rise to 642 million by 2040.1 In simpler terms, 1 in every 11th adult individual globally, is a patient of diabetes. Moreover, every 6 seconds, 1 person dies of diabetes.1

India houses 69.1 million patients of diabetes, with >50% of the cases remaining undiagnosed.2 Indian patients are inherently prone to develop diabetes and its complications, because of the ‘Asian Indian phenotype’, and influence of certain cultural practices. Asian-Indian phenotype includes certain unique clinical and biochemical abnormalities, like increased insulin resistance, greater abdominal adiposity i.e., higher waist circumference despite lower body mass index, lower adiponectin levels, and higher high sensitive C-reactive protein levels.3 The risk of vascular complications, like coronary artery disease, cardiovascular events (myocardial infarction, stroke), and chronic kidney disease is significantly increased in the Indian patients of diabetes.4-6 In fact, the prevalence of diabetic kidney disease is relatively higher in the patients from India, as compared to other Asian countries, indicative of poorer healthcare delivery.7

To optimize clinical management of T2DM, a proactive approach aimed to achieve the therapeutic goal of HbA1c within 6-months of diagnosis, has been recommended.8 However, at present, only about a third of the Indian patients are optimally controlled for blood glucose levels.9 An essential consideration is to address the comorbidities of T2DM, which contribute to the severe complications associated with this disease. As a holistic approach, management of hypertension and dyslipidemia should receive equal priority. The approach should be tailored according to the phenotype of the patient, including HbA1c level, duration of diabetes, presence of complications, and risk of hypoglycemia. Weight-reduction should be encouraged in obese patients.8

As Boehringer-Ingelheim, we continually strive for excellence in research and development, to bring innovative therapies for improving diabetes care across the world.

 

  •  

References

  1. ​IDF Diabetes Atlas, 7th edition, 2015. http://www.idf.org/about-diabetes/facts-figures. Accessed 28th Nov, 2016.
  2. IDF. Diabetes in India - 2015. http://www.idf.org/membership/sea/india. Accessed 28th Nov, 2016.
  3. Mohan V et al. Indian J Med Res. 2007 Mar;125:217-30.
  4. Mohan V et al. J Diabetes Sci Technol. 2010 Jan 1;4(1):158-70.
  5. Joshi SR et al. Diabetes Technol Ther. 2012 Jan;14(1):8-15.
  6. Singh AK et al. BMC Nephrol. 2013 May 28;14:114.
  7. Luk AO et al. Diabet Med. 2015 Oct 29. doi: 10.1111/dme.13014.
  8. Del Prato S et al. Int J Clin Pract Suppl. 2007 Dec;(157):47-57.
  9. Unnikrishnan R et al. Diabetes Technology & Therapeutics. 2014;16(9):596-603.

 

We recognize that the Internet serves a global community. The pharmaceutical industry, however, is subject to country specific regulatory considerations, which affect the information we can provide on our products. In addition the registration status of pharmaceutical products may not be the same in different regions of the world and the approved product labels may also differ according to country specific requirements.

Therefore please check the registration details of this/these product(s) locally in order to get up-to-date information.